Click Here To PrintIn August 2019, the New England Journal of Medicine published a research article1 titled “An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes”. There were 76 participants in the research, 55 of whom were 18 years old or younger. Research “subjects” (a word commonly used in place of “participants”)...